Alpha-1 proteinase inhibitor, human


Generic Medicine Info
Indications and Dosage
Intravenous
Emphysema
Adult: As maintenance in patients w/ severe alpha1-proteinase inhibitor deficiency: 60 mg/kg once wkly via infusion approx 0.08 mL/kg/min. Adjust infusion rate based upon patient tolerability.
Contraindications
Hypersensitivity. IgA deficient patients w/ antibodies against IgA.
Special Precautions
Patient at risk for fluid overload. Pregnancy and lactation.
Adverse Reactions
Significant: Risk of infection transmission (e.g. viruses such as Creutzfeldt-Jakob disease). Hypersensitivity reactions (e.g. anaphylaxis).
Nervous: Dizziness, somnolence, flu-like symptoms, headache, paraesthesia, asthenia.
CV: Flushing, chest pain or discomfort hypotension, tachycardia, vasodilatation, peripheral oedema.
GI: Nausea, oral candidiasis, sore throat.
Resp: Dyspnoea, upper resp tract infection, cough, sinusitis.
Hepatic: Increased hepatic enzyme.
Genitourinary: UTI.
Haematologic: Haemorrhage.
Musculoskeletal: Musculoskeletal pain, back pain, weakness.
Dermatologic: Pruritus, urticaria.
Others: Infusion-site reactions, fever, chills.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Closely monitor clinical state (e.g. vital signs), infusion rate, and signs of infusion-related reactions e.g. anaphylactic reactions. Monitor α1-PI serum levels and lung function.
Action
Description: Human alpha-1 proteinase inhibitor is the primary anti-protease in the lower resp tract inhibiting serine proteases e.g. neutrophil elastase, an enzyme that aids in the proteolytic destruction of the connective tissue framework of the lung parenchyma. It protects lung tissue proteolysis in individuals deficient in alpha1-proteinase inhibitor.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: Approx 1 hr.
Distribution: Volume of distribution: Approx 3.5 L.
Excretion: Elimination half-life: 5-6 days (metabolic).
Storage
Store below 25°C.
References
Anon. Alpha1-proteinase Inhibitor. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/08/2017.

Anon. Glassia Injection Solution (Baxalta US Inc.). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/08/2017.

Buckingham R (ed). Alpha1-proteinase Inhibitor. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2017.

McEvoy GK, Snow EK, Miller J et al (eds). α1-Proteinase Inhibitor (Human). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/08/2017.

Disclaimer: This information is independently developed by MIMS based on Alpha-1 proteinase inhibitor, human from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in